We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostic Accuracy of Histoplasma Urine Antigen Assay Evaluated

By LabMedica International staff writers
Posted on 29 Nov 2018
Print article
Image: The ALPHA Histoplasma Enzyme Immunoassay (EIA) test kit (Photo courtesy of IMMY).
Image: The ALPHA Histoplasma Enzyme Immunoassay (EIA) test kit (Photo courtesy of IMMY).
Histoplasmosis is an endemic mycosis in many regions of Latin America. In the human immunodeficiency virus (HIV) infected population it manifests as progressive disseminated histoplasmosis (PDH), an entity hard to diagnose since the causative fungi, Histoplasma capsulatum, is slow growing and requires advance biosafety for its handling.

The standard of reference for PDH diagnosis is the isolation of Histoplasma capsulatum from a non-respiratory sample, typically bone marrow or peripheral blood, or the visualization of yeast-like structures in the histopathologic examination. In the USA, histoplasmosis is also endemic, and its PDH presentation is commonly diagnosed by the detection of Histoplasma urine antigen (HUAg).

Scientists at The National Institute of Medical Sciences and Nutrition Salvador Zubirán (Tlalpan, Mexico City, Mexico) conducted a multicenter, prospective, diagnostic test study in two secondary and eight tertiary-care facilities from seven states of Mexico, from December 2015 to October 2017. At least 5 mL of peripheral blood were inoculated in a BD BACTEC Myco F/ Lytic vial; for bone marrow aspirates, a similar amount (5 mL) was inoculated in a BACTEC Myco F/ Lytic and a BACTEC Peds Plus F (3 mL), and 1 mL in a Löwenstein-Jensen and Sabouraud solid media.

The team evaluated the diagnostic accuracy of IMMY ALPHA Histoplasma Enzyme immunoassay (EIA) Test Kit. The scientists included 288 cases for this analysis. From these patients, the central laboratory processed 1,068 samples: 277 blood cultures, 252 bone marrow aspirate cultures, 104 biopsies for tissue culture, 147 biopsies for the histopathologic examination, and 288 urine samples for HUAg detection. They classified 85/288 (29.5%) patients as PDH–proven, 28.2% (24/85) based on positive histopathologic examination and positive culture, 58.8% (50/85) by positive culture only and 12.9% (11/85) by positive histopathologic exam only. The sensitivity of ALPHA-HUAg was 67.1% (95% CI, 56–76.8%) and the specificity was 97.5% (95% CI, 94.3%-99.1%). The positive likelihood ratio was 27.2 (95% CI; 11.6–74.4). In 10.5% of the PDH–proven patients, a co-existing opportunistic infection was diagnosed, mostly disseminated Mycobacterium avium complex infection.

The authors concluded that ALPHA-HUAg is a useful test for the diagnosis of PDH, in patients with high level of suspicion in endemic regions for H. capsulatum, and may favor early targeted-antifungal treatment, thus improving the prognosis of these frail HIV-patients. Nevertheless, the culture-based approach should ensue simultaneously since co-infections are frequent and a negative result of ALPHA-HUAg does not discard PDH in patients from endemic regions for H. capsulatum. The study was published on November 5, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
National Institute of Medical Sciences and Nutrition Salvador Zubirán

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.